Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (FY)Nov 28, 2025 | (Q4)Nov 28, 2025 | (Q3)Aug 29, 2025 | (Q2)May 30, 2025 | (Q1)Feb 28, 2025 | (FY)Nov 29, 2024 | (Q4)Nov 29, 2024 | (Q3)Aug 30, 2024 | (Q2)May 31, 2024 | (Q1)Mar 1, 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 10.53%23.77B | 10.49%6.19B | 10.72%5.99B | 10.62%5.87B | 10.27%5.71B | 10.80%21.51B | 11.05%5.61B | 10.59%5.41B | 10.24%5.31B | 5.18B |
| Operating revenue | 10.53%23.77B | 10.49%6.19B | 10.72%5.99B | 10.62%5.87B | 10.27%5.71B | 10.80%21.51B | 11.05%5.61B | 10.59%5.41B | 10.24%5.31B | --5.18B |
| Cost of revenue | 8.18%2.55B | 5.36%649M | 15.88%642M | 6.69%638M | 5.42%622M | 0.17%2.36B | -2.84%616M | -4.48%554M | 4.55%598M | 590M |
| Gross profit | 10.82%21.22B | 11.12%5.55B | 10.14%5.35B | 11.12%5.24B | 10.89%5.09B | 12.27%19.15B | 13.05%4.99B | 12.62%4.85B | 11.00%4.71B | 4.59B |
| Operating expense | 9.70%12.51B | 8.28%3.28B | 10.87%3.17B | 10.62%3.13B | 9.09%2.93B | 9.62%11.41B | 13.55%3.03B | 9.53%2.86B | 7.86%2.83B | 2.69B |
| Selling and administrative expenses | 10.53%8.06B | 7.88%2.15B | 13.91%2.05B | 11.28%2B | 9.27%1.86B | 7.82%7.29B | 14.48%1.99B | 6.33%1.8B | 5.76%1.8B | --1.7B |
| -Selling and marketing expense | 12.56%6.49B | 12.50%1.73B | 14.54%1.64B | 12.53%1.63B | 10.58%1.5B | 7.72%5.76B | 12.28%1.54B | 7.03%1.43B | 7.43%1.45B | --1.35B |
| -General and administrative expense | 2.88%1.57B | -7.68%421M | 11.48%408M | 6.20%377M | 4.26%367M | 8.21%1.53B | 22.58%456M | 3.68%366M | -0.56%355M | --352M |
| Research and development costs | 8.87%4.29B | 9.91%1.1B | 6.46%1.09B | 9.96%1.08B | 9.27%1.03B | 13.56%3.94B | 12.37%999M | 16.00%1.02B | 12.33%984M | --939M |
| Depreciation amortization depletion | -7.10%157M | -11.90%37M | -11.63%38M | -2.38%41M | -2.38%41M | 0.60%169M | 0.00%42M | 2.38%43M | 0.00%42M | --42M |
| -Depreciation and amortization | -7.10%157M | -11.90%37M | -11.63%38M | -2.38%41M | -2.38%41M | 0.60%169M | 0.00%42M | 2.38%43M | 0.00%42M | --42M |
| Operating profit | 12.47%8.71B | 15.53%2.26B | 9.09%2.17B | 11.88%2.11B | 13.42%2.16B | 16.41%7.74B | 12.28%1.96B | 17.38%1.99B | 16.07%1.89B | 1.91B |
| Net non-operating interest income (expenses) | -252.91%-263M | -122.68%-66M | -31.37%-67M | -65.85%-68M | -129.63%-62M | 10.26%172M | 20.75%291M | -88.89%-51M | -57.69%-41M | -27M |
| Non-operating interest income | ---- | ---- | ---- | ---- | ---- | 26.77%341M | ---- | ---- | ---- | ---- |
| Non-operating interest expense | 55.62%263M | 32.00%66M | 31.37%67M | 65.85%68M | 129.63%62M | 49.56%169M | 78.57%50M | 88.89%51M | 57.69%41M | --27M |
| Other net income (expenses) | 129.63%291M | 126.85%69M | -19.80%81M | -30.23%60M | 108.88%81M | -13,928.57%-982M | -46.02%-257M | 38.36%101M | 65.38%86M | -912M |
| Gain on sale of security | 138.89%43M | 175.00%12M | 91.67%23M | -50.00%2M | -66.67%6M | 325.00%18M | 20.00%-16M | 100.00%12M | -20.00%4M | --18M |
| Special income (charges) | --0 | --0 | --0 | --0 | --0 | ---1B | --0 | --0 | --0 | ---1B |
| -Less:Restructuring and mergern&acquisition | --0 | --0 | --0 | --0 | --0 | --1B | --0 | --0 | --0 | --1B |
| Other non-operating income (expenses) | --248M | --57M | -34.83%58M | -29.27%58M | 7.14%75M | ---- | ---- | 32.84%89M | 74.47%82M | --70M |
| Income before tax | 26.01%8.73B | 13.71%2.26B | 7.10%2.19B | 8.86%2.1B | 125.41%2.18B | 1.94%6.93B | 10.12%1.99B | 17.15%2.04B | 16.97%1.93B | 968M |
| Income tax | 16.99%1.6B | 32.47%408M | 15.92%415M | 14.85%410M | 6.61%371M | 0.00%1.37B | -5.23%308M | 5.29%358M | 0.56%357M | 348M |
| Earnings from equity interest net of tax | ||||||||||
| Net income | 28.24%7.13B | 10.28%1.86B | 5.23%1.77B | 7.50%1.69B | 192.10%1.81B | 2.43%5.56B | 13.49%1.68B | 20.03%1.68B | 21.47%1.57B | 620M |
| Net income continuous operations | 28.24%7.13B | 10.28%1.86B | 5.23%1.77B | 7.50%1.69B | 192.10%1.81B | 2.43%5.56B | 13.49%1.68B | 20.03%1.68B | 21.47%1.57B | --620M |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | 28.24%7.13B | 10.28%1.86B | 5.23%1.77B | 7.50%1.69B | 192.10%1.81B | 2.43%5.56B | 13.49%1.68B | 20.03%1.68B | 21.47%1.57B | 620M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | ||||||||||
| Net income attributable to common stockholders | 28.24%7.13B | 10.28%1.86B | 5.23%1.77B | 7.50%1.69B | 192.10%1.81B | 2.43%5.56B | 13.49%1.68B | 20.03%1.68B | 21.47%1.57B | 620M |
| Diluted earnings per share | 34.59%0.4884 | 16.80%0.1299 | 10.58%0.122 | 12.86%0.1153 | 202.92%0.1211 | 4.72%0.3629 | 16.87%0.1112 | 23.13%0.1103 | 23.68%0.1022 | 0.04 |
| Basic earnings per share | 35.11%0.4875 | 17.41%0.1299 | 11.17%0.122 | 12.89%0.115 | 204.42%0.1209 | 4.57%0.3608 | 17.34%0.1106 | 23.28%0.1098 | 23.76%0.1019 | 0.0397 |
| Dividend per share | ||||||||||
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.